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the proportion reporting adherence, 2) methods for assigning inter-
vention costs according to adherence, 3) which participants were
included in the economic analysis, and 4) statistical methods to
estimate cost-effectiveness in those who adhered. We provide rec-
ommendations on handling nonadherence in economic evaluations.
Methods: The National Health Service Economic Evaluation Database
was searched for recently published trials. We extracted information
on the methods used to assign shared costs in the presence of
nonadherence and methods to account for nonadherence in the
economic analysis. Results: Ninety-six eligible trials were identiﬁed.
For one-off interventions, 86% reported the number of participants
initiating treatment. For recurring interventions, 56% and 73%, respec-
tively, reported the number initiating and completing treatment,
whereas 66% reported treatment intensity. Most studies (23 of 31
[74%] trials and 42 of 53 [79%] trials of one-off and recurring
interventions, respectively) reported strict intention-to-treat oree front matter Copyright & 2016, International S
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cial Road, Melbourne, VIC 3004, Australia.complete case analyses. A minority (3 of 31 [10%] and 7 of 53 [13%],
respectively), however, performed a per-protocol analysis. No studies
used statistical methods to adjust for nonadherence directly in the
economic evaluation. Only 13 studies described patient-level alloca-
tion of intervention costs; there was variation in how ﬁxed costs were
assigned according to adherence. Conclusions: Most of the trials
reported a measure of adherence, but reporting was not comprehen-
sive. A nontrivial proportion of studies report a primary per-protocol
analysis that potentially produces biased results. Alongside primary
intention-to-treat analysis, statistical methods for obtaining an
unbiased estimate of cost-effectiveness in adherers should be
considered.
Keywords: adherence, compliance, economic evaluation, systematic
review, trial.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Treatment adherence has been deﬁned as the degree of correspond-
ence between a participant’s intended treatment and his or her
actual treatment [1]. Those who are unable to adhere to their
allocated treatment because they experience adverse effects, for
example, are more likely to have poorer clinical outcomes and
may also have higher health care costs [2,3]. Randomized con-
trolled trials (RCTs) are often considered the criterion standard
for assessing the cost-effectiveness of health care interventions.
The prevalence of treatment nonadherence in RCTs, however,
can be nontrivial [1]. Without clarity in reporting nonadherence
and the methods used to accommodate it, the ﬁndings from a
randomized trial may be difﬁcult to interpret.
Recent reviews of RCTs have highlighted vague and incomplete
reporting of adherence and inconsistency in how nonadherencewas incorporated in the analysis [1,4]. Trial-based economic
evaluations potentially suffer from similar shortfalls in reporting;
however, this has not previously been investigated as part of a
systematic review. The Consolidated Standards of Reporting Trials
(CONSORT) statement supports “intention-to-treat” (ITT) analyses,
which include all participants in the analysis group to which they
were randomly allocated regardless of treatment adherence [5].
The major beneﬁt of ITT analysis is that it preserves random-
ization and therefore eliminates selection bias in estimates of the
treatment effect and cost-effectiveness. Because ITT analyses do
not require adherence information, however, this may reduce the
motivation for collecting and reporting adherence. Information on
treatment adherence allows a more detailed exploration and
understanding of the costs and effects of treatment. For example,
adherence information can allow estimation of treatment cost-
effectiveness in participants who adhere to the intervention,ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ence is different from that of the RCT [6].
There has been little discussion about the unique challenges
presented by nonadherence in trial-based economic evaluations.
For example, shared (or overhead) costs might be allocated equally
across all those randomized to the treatment or, alternatively,
allocated to individuals according to how much treatment they
actually received. Furthermore, the type of nonadherence is poten-
tially important for economic evaluation. A prescription collected
from the pharmacy but not taken costs more than a prescription
written but never ﬁlled. Because nonadherence is likely to be
correlated with both costs and outcomes of care, the methods used
to account for it might also affect the inference drawn from the
cost-effectiveness summary measure. Therefore, it is important
that trial-based economic evaluations are transparent about the
extent of nonadherence and the methods used to account for it.
The aim of this article was to review published economic
evaluations conducted alongside randomized trials and identify
1) the proportion reporting information on adherence to the
randomized treatments, 2) the methods used for assigning
intervention costs to participants according to adherence, 3)
which randomized individuals were included in the primary
economic analysis, and 4) statistical methods used to estimate
intervention cost-effectiveness in those who did adhere to it. We
also provide recommendations on improved handling of non-
adherence in trial-based economic evaluations.Methods
Search Strategy
The National Health Service Economic Evaluation Database (NHS
EED) provides structured abstracts for most of the economic
evaluations in the medical literature [7]. We searched the NHS
EED for studies that contained a reference to randomization or an
RCT by using the search terms “randomi*” and “RCT.” We
included economic evaluations with patient-level resource-use
data collected between randomization and the primary assess-
ment of outcome in an individually randomized parallel-arm RCT
of a health care intervention. Exclusion criteria were non-RCTs,
no economic evaluation detailed in the methods, cluster and
crossover randomized trials and other designs with within-
patient comparisons, trials in which the observational unit for
adherence was not the participant, feasibility studies, models or
long-term follow-up studies (even if partially based on RCT data),
and studies not published in English.
We conducted our search in February 2013 and restricted it to
studies published in 2011. This provided a sufﬁcient number of
articles reﬂecting recent methodological practice, and NHS EED
abstracts were not complete for all studies published more recently.
For economic evaluations that referred to a main trial article
(potentially with more information on treatment adherence), we
reviewed both together.
All data were extracted by one author (S.L.B.) using a prespe-
ciﬁed proforma. For studies in which there were uncertainties
about classiﬁcation, a second author (W.H.) also reviewed the
article, and consensus was reached through discussion.
Experimental Treatment Arm
For each trial, we designated an experimental treatment arm for
our analysis. Typically, this was the most experimental, newest,
or highest intensity (e.g., dose) treatment. In situations in which
this could not be determined (16 trials, 17%), we arbitrarily chose
the ﬁrst treatment arm mentioned within the Methods section of
the economic evaluation article.Nonadherence and Treatment Intensity
We deﬁned treatment nonadherence as an imperfect correspond-
ence between the intended course of randomly assigned treatment
and the actual treatment received [1]. We distinguished between
studies of interventions typically intended to be “one-off” in nature
(e.g., surgery) and those typically intended to be “recurring” (such as
behavioral therapy sessions or a course of pharmacotherapy). For all
studies, we attempted to ascertain from trial reports the number of
participants who received some of their randomly allocated treat-
ment (i.e., “initiated”). For “recurring” interventions, we also
extracted information on the number of participants who adhered
to their intended course of treatment (“completed”) and ameasure of
treatment “intensity” (such as the number of sessions or prescrip-
tions taken). It is common for the intended frequency or duration of
treatment to be patient speciﬁc (27 trials, 28%), particularly in trials
with a recurring intervention in which personalized dose titration or
stepped care is used. In such studies, it may be impossible to
calculate how many patients “completed” their intended course of
treatment; nonetheless, we estimated the proportion of all trials that
reported treatment “initiation,” “completion,” and “intensity.”
Deﬁnition of the Analysis Set
We recorded the type of analysis used in the primary economic
evaluation based on the information provided (e.g., CONSORT
diagrams) or the author’s own deﬁnition. Studies analyzed partic-
ipants in the treatment group they were randomized to (“analyzed
as randomized”) or according to the treatment they actually
received (“analyzed as treated”). For those who were analyzed as
randomized, we also recorded whether all randomized partici-
pants were included in the analysis (“strict ITT”). Studies often do
not include all participants in the analysis—for example, excluding
those who withdrew or with no follow-up data (“complete case”
analysis). In addition, “per-protocol”analyses exclude participants
violating the protocol, for example, participants not completing
treatment or not meeting inclusion criteria.
Methods for Costing the Interventions
For studies that reported nonadherence or a measure of treat-
ment intensity, we extracted information about the methods
used for calculating intervention costs, provided this was
reported in sufﬁcient detail.
We categorized each component of the intervention costs on
the basis of three criteria (Table 1): 1) Type of cost (ﬁxed/semi-
ﬁxed/variable) [8]; 2) the method for assigning shared costs to
participants (indirect/direct); and 3) where applicable, units used
for estimating variable costs for individuals. This allowed us to
assess the consistency of costing methods used in trials with
nonadherence.
We also recorded information on any statistical methods,
beyond an as-treated or per-protocol analysis, to estimate the
cost-effectiveness of an intervention in those able to adhere to it.Results
Our search identiﬁed 330 articles; 97 (29%) articles, reporting on
96 unique RCTs, satisﬁed the eligibility criteria (Fig. 1; see full list
of articles in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2015.07.009).
For 57 (59%) trials, the primary economic evaluation was a
cost-effectiveness or cost-utility analysis, whereas in 37 (39%) it
was a cost-consequence analysis, in 1 (1%) a cost-beneﬁt analysis,
and in 1 (1%) a cost-minimization analysis. Interventions eval-
uated included 20 (21%) pharmacological, 25 (26%) surgical, 9 (9%)
diagnostic, 15 (16%) behavioral/psychosocial/educational, and
Table 1 – Criteria for assessing methods used to calculate patient-level intervention costs.
Criteria Subcategories Deﬁnition Example
1. Type of intervention cost
Fixed costs Shared costs that are not affected by within-trial
adherence to treatment
Costs of developing software for Internet-based
management for patients with asthma
Semi-ﬁxed costs Shared costs that are ﬁxed for a given range of
adherence to treatment but change in steps
above a given threshold
Staff costs for a physiotherapist leading group
lifestyle intervention sessions for which one
session would be required if 1–12 patients
adhere, two sessions would be required if 13–24
patients adhere, and so on
Variable costs Costs that vary proportionately with changes in
activity at the individual patient level
Costs associated with drugs and consumables
2. The method used for assigning shared costs to patients
Indirect allocation Costs are allocated to all patients for whom the
resource was intended regardless of the
amount of resource an individual patient used
The cost of developing the software is shared
between all patients who were randomized to
the intervention arm intended to receive
Internet-based management of their asthma
Direct allocation Costs are allocated to patients in direct
proportion to the amount of resources they
used
Only patients who attend their group lifestyle
session are allocated the staff costs of the
physiotherapist who is leading it
3. Units used for estimating variable costs for individual patients
NA The measurement units used to estimate
variable costs
Cost per consultation or cost per minute might be
used for a GP visit
GP, general practitioner; NA, not applicable.
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in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2015.07.009).
Reporting of Adherence
A total of 37 (39%) trials had a one-off intervention (Table 2), with
most being surgical. Most (32; 86%) reported the number of
participants initiating treatment, of which more than half (18;
56%) reported having participants who did not initiate the treat-
ment to which they were randomized.
Overall, 59 (61%) trials had a recurring intervention. Of these,
42 had an intervention lasting more than 1 month, 11 had an
intervention lasting less than 1 month, and 6 had insufﬁcient
information to determine the intervention duration. Most of the
trials with a recurring intervention had pharmacological or
behavioral/psychosocial/educational interventions.
For recurring interventions, the most commonly reported
adherence information was the number of participants complet-
ing treatment (reported in 73% of the trials) and various measures
of treatment intensity (reported in 66% of the trials). Trials with
recurring interventions were less likely to report the number of
individuals who initiated treatment, but this information was
still reported in more than half of the articles (56%). Almost all
the trials with a recurring intervention (55; 93%) reported at least
one of the measures of adherence (initiation, completion, or
treatment intensity), but only around one-third (22; 37%) reported
all three types. The measure of treatment intensity that was
reported appeared to differ slightly across the different types of
interventions. Trials with a behavioral/psychosocial/educational
intervention were more likely to report the number of partic-
ipants receiving different (discrete) quantities of treatment units.
Trials of other interventions often reported the mean, median, or
total number of treatment units received.
Analysis Set Used for the Primary Economic Evaluation
For a small number of trials (12; 13%), it was unclear which
groups individuals were analyzed in (Table 3). In the remainingtrials (84; 88%), participants were analyzed as randomized; for a
number of these trials (n ¼ 22), this was inferred from but not
explicitly stated in the article.
In trials in which individuals were analyzed as randomized, the
most common type of analysis was a strict ITT including all
randomized individuals (18 trials, 58% of one-off interventions,
and 24 trials, 45% of recurring interventions). An analysis using only
complete cases was performed in 18 (34%) trials with a recurring
intervention and 5 (16%) trials with a one-off intervention. For both
one-off and recurring interventions, around 20% of the trials used a
per-protocol analysis for the primary economic evaluation, for
example, excluding participants who were unable to adhere to their
treatment. There were a small number of trials in which participants
were analyzed as randomized, but the analysis set was unclear.
Intervention Costs
Only 13 studies gave a clear description of how intervention costs
were calculated and allocated to individual participants (Table 4).
Most of the ﬁxed costs were indirectly allocated, meaning the
cost of the ﬁxed resource was evenly shared between all partic-
ipants randomized to the treatment arm regardless of adherence.
The exceptions were primarily trials in which the cost of the
shared resource (e.g., equipment, hospital overheads, materials,
therapist training, and therapist supervision) was subsumed into
the total cost of all resources used in administering the inter-
vention (both ﬁxed and variable) [11,16]. In these cases, the total
cost of all intervention resources was used to derive a unit cost
for the entire intervention rather than for each resource sepa-
rately. The unit cost was then directly allocated to participants
who received (or adhered to) treatment on the basis of the
amount of treatment they received.
Semi-ﬁxed costs were either directly or indirectly allocated
depending on the trial. For example, Morris et al. [17] chose to
share staff costs for physiotherapists administering a postsurgery
rehabilitation program evenly between all randomized individu-
als (indirect allocation). Irvine et al. [14] chose to allocate the cost
of physiotherapists/facilitators administering lifestyle education
sessions only to those who attended (direct allocation).
Table 2 – Number of trials reporting adherence and measures of treatment intensity for the experimental treatment arm.
Category One-off interventions Recurring interventions
Surgical
(n ¼ 25)
Diagnostic
(n ¼ 7)
Other*
(n ¼ 5)
Total
(n ¼ 37)
Pharmacological
(n ¼ 19)
BPE
(n ¼ 15)
Other*
(n ¼ 25)
Total
(n ¼ 59)
Reported the number of participants initiating treatment 22 (88) 6 (86) 4 (80) 32 (86) 13 (68) 7 (47) 13 (52) 33 (56)
r95% 6 (27) 3 (50) 1 (25) 10 (31) 3 (23) 4 (57) 7 (54) 14 (42)
495%, o100% 6 (27) 1 (17) 1 (25) 8 (25) 3 (23) 1 (14) 3 (23) 7 (21)
100% 10 (45) 2 (33) 2 (50) 14 (44) 7 (54) 2 (29) 1 (8) 10 (30)
Not reported for each treatment arm† 0 (0) 0 (0) 2 (15) 2 (6)
Reported the number of participants completing treatment – – – – 15 (79) 12 (80) 16 (64) 43 (73)
Reported measure(s) of treatment intensity‡ 12 (63) 11 (73) 16 (64) 39 (66)
Number of participants receiving different (discrete) quantities
of treatment
– – – – 1 (8) 7 (64) 1 (6) 9 (23)
Mean/median/total number of treatment units or treatment
exposure (e.g., time) received by participants
– – – – 7 (58) 6 (55) 12 (75) 25 (64)
Percentage of treatment units successfully administered to
participants
– – – – 0 (0) 0 (0) 1 (6) 1 (3)
Percentage of participants achieving a treatment threshold – – – – 4 (33) 2 (18) 3 (19) 9 (23)
Note. Values are n (%).
BPE, behavioral/psychosocial/educational.
* Details of the other types of interventions are given in the Appendix.
† One trial reported the number of participants initiating treatment by factor level (but not by treatment arm), and one trial reported the number of participants initiating treatment overall.
‡ Trials may have reported more than one measure of treatment intensity.
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Table 3 – Analysis set used for the primary eco-
nomic evaluation.
Type of analysis set One-off
interventions
(n ¼ 37)
Recurring
interventions
(n ¼ 59)
Analyzed as
randomized*
31 (84) 53 (90)
Strict ITT (complete
data or use of
imputation†)
18 (58) 24 (45)
Complete case 5 (16) 18 (34)
Per protocol‡ 3 (10) 7 (13)
Per protocol‡ and
complete cases
3 (10) 3 (6)
Analysis set unclear 2 (6) 1 (2)
Analyzed as treated 0 (0) 0 (0)
Unclear 6 (16) 6 (10)
Note. Values are n (%).
ITT, intention-to-treat.
* Eleven trials with a one-off intervention and 11 trials with a
recurring intervention did not explicitly state that they analyzed
participants as randomized, but this could be inferred from the
results tables.
† There were a total of 27 trials overall that reported using
imputation for missing economic outcomes (costs, effects, or
both): 15 (4 one-off and 11 recurring) of these performed a strict
ITT, whereas 12 (1 one-off and 11 recurring) performed a per-
protocol and/or complete case analysis (i.e., imputed missing
outcomes only for a selection of patients).
‡ Reasons for being classiﬁed as a per-protocol analysis include the
authors stating a per-protocol analysis; excluding participants
who did not satisfy the inclusion criteria (after randomization);
excluding participants who did not initiate treatment; and
excluding participants for treatment complications, treatments
switching, or converted surgical procedures.
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costs depended primarily on the type of resource being consid-
ered, but there was some variation across similar resources. For
example, staff costs associated with treatment sessions or con-
sultations were generally assigned to individuals on the basis of
the number of sessions attended [9,12,21]. The staff (neuro-
surgeon and anesthetist) costs associated with surgery in van
den Akker et al. [19] were directly assigned to participants using
the number of minutes taken to complete the procedure.
Incorporating Adherence into Economic Evaluations
None of the articles included in our review used statistical
methods to adjust for nonadherence or incorporate adherence
information directly into the economic evaluation.Discussion
Main Findings
Lack of adherence to randomly assigned treatment and how this
is accommodated in the analysis are important issues for the
interpretation of economic evaluation conducted alongside RCTs.
In more than half of the trials, there were participants who
reportedly did not initiate their randomly assigned treatment.
Encouragingly, 93% of the trials with a recurring intervention and
86% of the trials with one-off interventions reported at least one
measure of adherence. Treatment adherence, however, is notcomprehensively reported—almost 30% of economic evaluations
of recurring interventions failed to report the number of partic-
ipants who completed treatment, and even more (34%) failed to
report a measure of treatment intensity. Among the 22 (37%)
trials with a recurring intervention that did report all three
categories of adherence, various approaches to reporting were
used, with most relying on a combination of ﬂow chart/tables and
text (see, e.g., [22–24]).
Approximately 20% of the trials reported a primary per-
protocol analysis potentially excluding participants with low
treatment adherence and biasing results. There was little con-
sistency in the assignment of shared costs to individuals, with
both direct (reﬂecting patient treatment adherence) and indirect
(ignoring patient treatment adherence) methods being used.
None of the economic evaluations incorporated statistical meth-
ods to provide an unbiased estimate of cost-effectiveness among
treatment compliers.
Strengths and Weaknesses
Our study used a systematic approach to identify articles. To our
knowledge, it is the ﬁrst review of adherence reporting and
analysis methods in trial-based economic evaluations of phar-
macological and nonpharmacological interventions.
Because of journal space constraints, information on the
economic methods and results was often sparse, making it
difﬁcult to categorize the methods used by authors with cer-
tainty. This was particularly the case for trials that report both
clinical and economic results in the same article. We did not
contact trial authors to verify our interpretation of the methods
that they used, and we did not review trial protocols. Therefore,
we may have misclassiﬁed the analysis set or cost allocation
methods used. Furthermore, we restricted our analysis to the
most recent year of economic evaluations with complete data
available in the NHS EED. Our review, however, provides a
snapshot of treatment nonadherence reporting and analytical
methods as described in recent trial-based economic evaluations.
The relationship between intervention costs and treatment
adherence is often complex. For example, in van der Meer et al.
[10], an electronic spirometer was provided to each patient for
home monitoring of asthma. Once the spirometer has been given,
the cost is incurred regardless of subsequent adherence. How-
ever, if a patient was to withdraw from the trial immediately after
randomization, then it is possible that the cost of the spirometer
could be avoided. Because of such complexities, it is very difﬁcult
to judge from an economic evaluation report whether costing
methods have appropriately accounted for these opportunity
costs of treatment adherence [25].
Comparison with Previous Research
The issues considered here bridge two relatively disparate areas
of previous research. First, reviews considering the reporting and
appropriate analysis of nonadherence in clinical trials [1,4,26].
Second, research on the impact of drug nonadherence on the
costs and outcomes of care, which has been primarily evaluated
using decision analysis models [2,27–29]. Most of these authors
have highlighted the need for improvements in the collection of
adherence data and clear deﬁnitions of the types of nonadher-
ence being measured. Our review suggests that such improve-
ments are also needed for the reporting of trial-based economic
evaluations.
Dodd et al. [1] found that the number of patients initiating
treatment was reported in 50%, 68%, and 83% of the trials with
long-term, short-term, and one-off interventions, respectively.
They also found that 77% of the trials with short- or long-term
interventions at least partially reported the number of patients
Table 4 – Categories of intervention costs and the methods used for assigning costs to study participants.
Article Analysis set
for primary
economic
evaluation
Intervention Cost component Fixed, semi-
ﬁxed, or
variable cost
Direct or
indirect
allocation
Units used for direct
allocation
Chuang et al. [9] Strict ITT Ultrasound therapy for patients with hard-to-heal leg ulcers
1 Ultrasound machines Fixed Indirect NA
2 Nurse consultations Variable Direct Per consultation (by
treatment location)
3 Compression therapy Variable Direct Per consultation (by high/
low compression applied)
van der Meer et al.
[10]
Strict ITT Internet-based self-management for patients with asthma
1 Materials (software support, electronic spirometer) Fixed Indirect NA
2 Personnel time (development of educational aids,
group education sessions, data review, and patient
communication)
Semi-ﬁxed Indirect NA
3 Patient costs (travel, time, Internet, and text
messaging costs)
Variable Direct Per treatment session, login,
or text message
Wordsworth et al.
[11]
Strict ITT Clomifene citrate treatment for couples with unexplained infertility
1 Equipment (scanning machines and couches) Fixed Direct Per treatment cycle*
2 Hospital overheads (administration, heating,
cleaning, property maintenance)
Fixed Direct
3 Staff time (nurse, subfertility sister, receptionist,
secretary, senior registrar)
Fixed Direct
4 Consumables Variable Direct
Hopkins et al. [12] Strict ITT Nephrologist/nurse-based multifaceted intervention for patients with stage 3 to stage 4 chronic kidney disease
1 Nephrologists’ time (visits, meetings,
communications)
Fixed Indirect NA
2 Nurse visits Variable Direct Per visit
Hedman et al. [13] Strict ITT Internet-based cognitive-behavior therapy (CBT) for patients with social anxiety disorder
1 Therapist time (spent responding to patient
messages)
Variable Direct Per minute
2 Patient time (domestic loss) Variable Direct Per minute
Irvine et al. [14] Strict ITT Lifestyle intervention (including group education sessions, peer support sessions, physiotherapy, and telephone peer support) for patients at a
higher risk of developing diabetes
1 Telephone peer support staff (volunteers) training
costs
Fixed Indirect NA
2 Facilitator and/or physiotherapist time for
administering various group sessions
Semi-ﬁxed Direct Per treatment session (unit
cost dependent on
attendance rate)
3 Telephone peer support staff (volunteers) time Variable Direct Per minute
Mittman et al. [15] Per protocol Budesonide/formoterol added to tiotropium for treating patients with chronic obstructive pulmonary disease
1 Study drugs Fixed Indirect NA
continued on next page
V
A
L
U
E
IN
H
E
A
L
T
H
1
9
(2
0
1
6
)
9
9
–
1
0
8
104
Patel et al. [16] Complete cases Motivational enhancement therapy (MET) and CBT for patients with type 1 diabetes
1 Materials (manual, information sheets, Accu-Test CD-
ROM, tape recorder, tapes)
Fixed Direct Per treatment session (by
session type: MET/CBT)†
2 Therapist training Fixed Direct
3 Therapist supervision Fixed Direct
4 Therapist time for delivery of treatment sessions Variable Direct
5 Therapist time for chasing nonattenders Variable Direct
Morris et al. [17] Unclear Rehabilitation program (12 supervised group exercise classes) and an educational booklet for patients who have undergone discectomy or lateral
nerve root decompression surgery
1 Booklet cost Fixed Indirect NA
2 Staff costs (physiotherapist) for rehabilitation
program classes
Semi-ﬁxed Indirect NA
Whitehurst et al.
[18]
Strict ITT Acupuncture (as an adjunct to exercise-based physical therapy) for patients with osteoarthritis of the knee
1 Study treatment sessions (advice and exercise with/
without acupuncture)
Variable Direct Per treatment session (by
session type)
van den Akker
et al. [19]
Strict ITT Tubular diskectomy for patients with lumbar disk–related sciatica
1 Operating room (including standard staff, equipment,
and overheads)
Variable Direct Per minute
2 Specialist staff (neurosurgeon and anesthetist) Variable Direct Per minute
3 Speciﬁc operating equipment (incorporating purchase
price, yearly use, depreciation, maintenance, and
interest)
Fixed Indirect NA
4 Consumables Variable Direct Per item
Thomas et al. [20] Complete cases Ion-exchange water softener installed into the home of children with atopic ezcema
1 Ion-exchange water softener Fixed Indirect NA
2 Installation Fixed Indirect NA
3 Salt Variable Direct Per salt box‡
4 Consultation Variable Direct Per consultation
Cockayne et al.
[21]
Complete cases Cryotherapy using liquid nitrogen for patients with verrucae (plantar warts)
1 Equipment Fixed Direct Per treatment session§
2 Liquid nitrogen Variable Direct Per treatment session
3 Clinician’s (GP, nurse, or podiatrist) time Variable Direct Per treatment session
GP, general practitioner; ITT, intention-to-treat; NA, not applicable.
* Unit cost for each treatment cycle was hospital speciﬁc (n ¼ 5) and based on the total cost of all resources used for the intervention divided by the total number of treatment cycles delivered by
that hospital.
† Unit cost for each type of treatment session (MET/CBT) was based on the total cost of all resources used in delivering that session type. An average cost per session/per person was derived on
the basis of “assuming 20% higher attendance rates.”
‡ Allocated on the basis of assumed (rather than actual) consumption, determined using the number of residents in the house.
§ Unit cost based on the total annual cost of the equipment divided by the maximum number of treatments it could provide in a year (assuming an average of 20 min per treatment session).
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 9 9 – 1 0 8106completing treatment. These ﬁgures compare closely with our
ﬁndings (Table 2). Zhang et al. [4] found that slightly less than
half (46%) of the trials with an oral pharmacological intervention
reported adherence results, whereas Gossec et al. [26] found even
lower rates. We found higher adherence reporting rates, 63% to
79%, depending on the aspect of treatment adherence being
considered. This may be because economic evaluations are more
likely to provide details of treatment intensity in estimating the
cost of health care.
Hughes et al. [29] found that adherence was not included
routinely in pharmacoeconomic analysis based on decision
analysis models and recommended that net-beneﬁt regression,
including a treatment and adherence interaction term, would
allow trial-based economic evaluations to explore any impact of
nonadherence on cost-effectiveness. Despite this recommenda-
tion, none of the economic evaluations included in our review
used this approach to explore the impact of adherence.
Implications
We found that the reporting of adherence in trial-based economic
evaluations was not comprehensive. Numerous deﬁnitions of
nonadherence appear in the economic literature, and this
increases the challenges with making comparisons across studies
[2]. Appropriate deﬁnitions of adherence may also depend on the
context of the study and the type of intervention. Some authors
have provided useful guidance on the measures of adherence
that trials should report [1]. This guidance applies equally well to
the reporting of economic evaluations. For medication use in
particular, formal deﬁnitions of compliance and persistence have
already been proposed [30]. Failure to provide adequate informa-
tion on adherence makes it difﬁcult to synthesize results of trials
with different degrees of adherence or to generalize trial results
to clinical practice where adherence to therapy may be different.
We found that only a small number of articles reported
costing methods in sufﬁcient detail for us to determine exactly
how intervention costs were allocated at an individual patient
level. There was variable practice in how studies directly or
indirectly assigned shared costs to participants on the basis of
their degree of adherence. For variable resources, we found that
some trials chose to directly allocate costs on the basis of much
greater levels of detail (e.g., per minute for the use of the
operating room or specialist staff time in van den Akker et al.
[19]), whereas others used less detail and applied an average unit
cost based on a higher level of aggregation (e.g., per consultation
for nurse consultations in Chuang et al. [9]). The widely cited
textbook on economic evaluation by Drummond et al. [31] states
that “…there is no unambiguously right way to apportion
[shared] costs” and that “…analysts need to form a judgement
on how accurate (or precise) cost estimates need to be within a
given study.” Direct allocation of costs according to the precise
amount used by each patient is likely to produce the most
accurate individual cost estimates and allow the most detailed
exploration of the relationship between adherence, costs, and
outcomes. Simple methods for assigning costs (e.g., indirect
assignment of ﬁxed costs to participants regardless of adherence
to treatment) have the potential to underestimate the variance in
costs between individuals and therefore the conﬁdence interval
surrounding the net monetary beneﬁt (NMB) statistic.
Poor reporting also made it difﬁcult to judge the analysis set
used to estimate cost-effectiveness. For many articles, the anal-
ysis set used in the economic evaluation had to be inferred from
the results presented. The CONSORT statement recommends
that articles clearly describe the speciﬁc set of participants
included in each analysis [5]. Likewise, the recent Consolidated
Health Economic Evaluation Reporting Standards checklist for
reporting economic evaluations highlights the importance ofstating whether ITT analysis was used and methods for handling
missing data [32].
In those studies that provided sufﬁcient information, the most
frequent primary analysis set was ITT using a complete or
partially imputed data set. This seems appropriate given that
economic analyses are most likely to be conducted alongside
phase III pragmatic trials aimed at informing policy. The key
beneﬁts of ITT analysis are that it decreases potential for
selection bias by preserving randomization as well as providing
a “real-world” estimate of cost-effectiveness, attenuated by non-
adherence. Interestingly, the impact of nonadherence on cost-
effectiveness results from an ITT analysis will depend on
whether the incremental cost-effectiveness ratio (ICER) or the
NMB is used to summarize results (see Appendix in Supplemen-
tal Materials found at: http://dx.doi.org/10.1016/j.jval.2015.07.009).
Under plausible assumptions, the ITT ICER remains constant as
the adherence rate varies. However, the NMB is affected by the
rate of adherence and approaches zero as nonadherence
approaches 1. Therefore, in trial-based economic evaluation
aimed at informing policy, the NMB is likely to be a more
appropriate cost-effectiveness summary measure. Such results
can be shown explicitly for a trial in which participants are
exclusively adherers or nonadherers (e.g., a surgical trial); how-
ever, in a trial in which partial adherence is possible (e.g.,
pharmacological trials), the resulting impact of nonadherence
on the ITT ICER and the ITT NMB may be further complicated. It
is also worth noting that adherence in a trial may be better than
in routine practice, for example, because of increased patient
monitoring or the selection of trial participants on the basis of
their ability to adhere to treatment. The impact of this on cost-
effectiveness is ambiguous [6].
We found that only around half of the studies actually used a
strict ITT analysis. In some studies, it may be impossible to
include all patients for reasons of missing data or protocol
violations. The Food and Drug Administration guidance on
“Statistical Principles for Clinical Trials” refers to a “full analysis
set” that it deﬁnes as “the analysis set which is as complete as
possible and as close as possible to the intention-to-treat ideal of
including all randomised subjects” [33]. It is likely that a number
of studies in our review that did not use a strict ITT analysis were
still attempting to follow the ethos of such guidelines.
Although ITT analysis is optimal for assessing the pragmatic
question of whether a policy of assigning patients to a given
therapy is likely to be cost-effective despite imperfect adherence
to therapy, ITT analyses do not shed light on the relationship
between adherence and cost-effectiveness. Understanding this
relationship is crucial for distinguishing an intervention that is
not cost-effective even in participants who adhere to it from one
that is not cost-effective because a high proportion of individuals
do not adhere to it. For the latter, there may be a case for
“compliance-enhancing” modiﬁcations to treatment to improve
cost-effectiveness [34,35]. Furthermore, details on cost-
effectiveness among adherers may be valuable for assessing the
transferability of trial results, through decision analysis models,
to other settings in which adherence is known to differ.
A small proportion of studies used a per-protocol comparison
as the primary analysis to examine cost-effectiveness in those
who adhered to treatment. This potentially introduces selection
bias because the comparison is no longer between randomly
allocated treatment groups (see Appendix in Supplemental
Materials). Several methods exist for estimating the causal treat-
ment effect in trials with nonadherence [36]. Instrumental vari-
able analysis [37,38] is likely to offer the simplest starting point,
and this approach could be readily extended to NMB analysis. A
lack of examples in the cost-effectiveness studies we identiﬁed
suggests that this is a fertile area for further applied and
methodological research.
Notes. 1 Includes five review papers, one symposium paper, two feasibility studies, two studies not 
reporting within-trial results, two studies which did not discuss costs in the methods section and 17 
studies where participants were not randomised. 2 Includes eight cluster randomised trials. 3 For 
example, where ventilation systems were installed into homes. 4 There were three Health Technology 
Assessment reports which related to trials published in a separate article already in our review. 
Additionally, there were two articles which each reported two trials. 
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 9 9 – 1 0 8 107Recommendations1. A CONSORT diagram should be included with all trial-based
economic evaluations detailing exactly which trial partici-
pants are included in the analysis set used for primary and
secondary economic analyses.2. Key items of adherence to be measured during the trial should
be prespeciﬁed. More detailed recommendations on the
appropriate measures of adherence have been described else-
where [1,30]. There should be, however, transparent reporting
of these key items of adherence within the report of the trial-
based economic evaluation.3. Greater justiﬁcation and detail should be provided (in the
main report or in an appendix) on the methods used to
allocate shared costs to individual participants who adhere
or do not adhere to treatment.4. If nonadherence is prevalent, then trial-based economic
evaluations aimed at informing policy should report primary
ITT analyses based on the NMB rather than on the ICER. Under
plausible assumptions, it can be shown that the ICER is
invariant to the rate of nonadherence, whereas the NMB is
inﬂuenced by changes in the adherence rate (see Appendix in
Supplemental Materials).5. As a sensitivity analysis, statistical methods to estimate cost-
effectiveness in participants who adhere to treatment should beconsidered. A per-protocol analysis will not provide an unbiased
estimate. The ITT ICER will provide such an estimate under
certain assumptions (see Appendix in Supplemental Materials).
Alternatively, an instrumental variable approach applied to the
NMB may be appropriate.
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